| Q91899486 | A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers |
| Q47399072 | An Automated System Combining Safety Signal Detection and Prioritization from Healthcare Databases: A Pilot Study. |
| Q92255891 | Anti-NASH Drug Development Hitches a Lift on PPAR Agonism |
| Q58587653 | Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? |
| Q36338313 | Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus. |
| Q30242051 | Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? |
| Q40141299 | Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes |
| Q38645244 | Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis. |
| Q37699907 | Deciphering the Roles of Thiazolidinediones and PPARγ in Bladder Cancer |
| Q38651175 | Diabetes drugs and the incidence of solid cancers: a survey of the current evidence. |
| Q38815202 | Drug therapies in type 2 diabetes: an era of personalised medicine. |
| Q51565743 | Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. |
| Q48344852 | Effects of combination of mitiglinide with various oral antidiabetic drugs in streptozotocin-nicotinamide-induced type 2 diabetic rats and Zucker fatty rats |
| Q90237753 | Evaluation of selected commercial pharmacotherapeutic drugs as potential pancreatic lipase inhibitors and antiproliferative compounds |
| Q64104750 | Expression of miR-490-5p, miR-148a-3p and miR-608 in bladder cancer and their effects on the biological characteristics of bladder cancer cells |
| Q47782346 | Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer |
| Q45073276 | Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes |
| Q61799673 | High Glucose with Insulin Induces Cell Cycle Progression and Activation of Oncogenic Signaling of Bladder Epithelial Cells Cotreated with Metformin and Pioglitazone |
| Q58795617 | Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators |
| Q92351177 | Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells |
| Q38804862 | Lipostar, a Comprehensive Platform-Neutral Cheminformatics Tool for Lipidomics |
| Q30238940 | Medical Management of Diabesity: Do We Have Realistic Targets? |
| Q30241952 | PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. |
| Q51706809 | PPARγ Modulation of Cytokine-Stimulated MUC16 (CA125) Expression in Breast and Ovarian Cancer-Derived Cells. |
| Q64119234 | PPARγ activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway |
| Q64055449 | PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells |
| Q48229258 | Patients with Nonalcoholic Fatty Liver Disease Have a Low Response Rate to Vitamin D Supplementation |
| Q41640163 | Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease |
| Q55356554 | Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study. |
| Q64965943 | Pioglitazone alleviates oxygen and glucose deprivation-induced injury by up-regulation of miR-454 in H9c2 cells. |
| Q55079635 | Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. |
| Q40389639 | Pioglitazone and bladder cancer: FDA's assessment |
| Q37576689 | Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis |
| Q42379243 | Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials |
| Q64269615 | Pioglitazone increases VEGFR3 expression and promotes activation of M2 macrophages via the peroxisome proliferator‑activated receptor γ |
| Q37179822 | Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries |
| Q91875408 | Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies |
| Q55406042 | Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis. |
| Q91644474 | Prospective of managing impaired brain insulin signalling in late onset Alzheimers disease with excisting diabetic drugs |
| Q38662765 | Review article: new treatments in non-alcoholic fatty liver disease. |
| Q88779484 | Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation |
| Q38654762 | SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials |
| Q47642298 | SGLT2 inhibitors: are they safe? |
| Q33748722 | Spatial Analysis of Ambient PM2.5 Exposure and Bladder Cancer Mortality in Taiwan. |
| Q57312974 | Stroke |
| Q38676257 | The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. |
| Q38622261 | The benefits of data mining |
| Q30250347 | The current role of thiazolidinediones in diabetes management |
| Q89881026 | The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety |
| Q38641190 | Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future |
| Q89258111 | Type 2 diabetes |
| Q33830390 | Within-class differences in cancer risk for sulfonylurea treatments in patients with type 2 diabetes (ZODIAC-55) - a study protocol. |